Catalyst Calendar

Tue, Jun 23, 2026

1 updates

7:00 AM

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held

Presentation / Abstract • Phase 1Poster presentation Wed, Jun 24, 2026, 5:20 PM CESTamylyx.com

Mon, Jun 8, 2026

1 updates

AMLX

9:00 AM

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL.

amylyx.com

Fri, May 15, 2026

1 updates

AMLX

12:11 PM

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic

amylyx.com

Thu, May 7, 2026

1 updates

AMLX

7:00 AM

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00

amylyx.com

Wed, May 6, 2026

1 updates

AMLX

9:00 AM

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Bank of America’s 2026 Health Care

amylyx.com

Tue, May 5, 2026

1 updates

AMLX

7:00 AM

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

The Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist Avexitide is being evaluated in the pivotal Phase 3 LUCIDITY clinical

amylyx.com

Thu, Apr 30, 2026

1 updates

AMLX

9:00 AM

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m.

amylyx.com